-
Health Care Select Sector SPDR (XLV $138.11)
- $138.11 P/E (TTM): 23.54X Cap: $34.77B
- View XLV Profile
- View Questions on XLV
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}
{tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}
{tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
{data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
-
Costco Wholesale Corporation (COST $967.90)
- $967.90 P/E (TTM): 55.86X Cap: $429.24B
- View COST Profile
- View Questions on COST
-
Lockheed Martin Corporation (LMT $471.31)
- $471.31 P/E (TTM): 26.05X Cap: $110.03B
- View LMT Profile
- View Questions on LMT
-
Walmart Inc. (WMT $103.49)
- $103.49 P/E (TTM): 42.91X Cap: $825.11B
- View WMT Profile
- View Questions on WMT
-
Xcel Energy Inc. (XEL $73.35)
- $73.35 P/E (TTM): 20.03X Cap: $43.38B
- View XEL Profile
- View Questions on XEL
-
Dollarama Inc. (DOL $188.77)
- $188.77 P/E (TTM): 42.04X Cap: $52.17B
- View DOL Profile
- View Questions on DOL
-
Intact Financial Corporation (IFC $277.97)
- $277.97 P/E (TTM): 22.41X Cap: $50.01B
- View IFC Profile
- View Questions on IFC
-
iShares S&P/TSX Capped Consumer Staples Index ETF (XST $59.97)
- $59.97 P/E (TTM): 13.48X Cap: $322M
- View XST Profile
- View Questions on XST
-
iShares S&P/TSX Capped Utilities Index ETF (XUT $30.59)
- $30.59 P/E (TTM): 21.23X Cap: $321M
- View XUT Profile
- View Questions on XUT
-
Consumer Staples Select Sector SPDR (XLP $80.32)
- $80.32 P/E (TTM): 24.24X Cap: $15.98B
- View XLP Profile
- View Questions on XLP
-
Health Care Select Sector SPDR (XLV $138.11)
- $138.11 P/E (TTM): 23.54X Cap: $34.77B
- View XLV Profile
- View Questions on XLV
-
Utilities Select Sector SPDR ETF (XLU $85.50)
- $85.50 P/E (TTM): 22.8X Cap: $21.24B
- View XLU Profile
- View Questions on XLU
-
Texas Pacific Land Corporation (TPL $937.17)
- $937.17 P/E (TTM): 46.9X Cap: $21.58B
- View TPL Profile
- View Questions on TPL
-
GFL Environmental Inc. subordinate voting shares (GFL $65.31)
- $65.31 Cap: $24.20B
- View GFL Profile
- View Questions on GFL
-
RTX Corporation (RTX $155.85)
- $155.85 P/E (TTM): 34.07X Cap: $208.61B
- View RTX Profile
- View Questions on RTX
Q: Good Day 5i team... thank you for your very valuable time, answers to questions and guidance. My question is, can you list out your top 10 ETF and or Equities you see as insulation/defensible should the over bought North American equity markets begin to slide. Thank you
-
BMO S&P 500 Index ETF (ZSP $99.89)
- $99.89 P/E (TTM): 25.3X Cap: $19.90B
- View ZSP Profile
- View Questions on ZSP
-
iShares S&P/TSX Canadian Dividend Aristocrats Index ETF (CDZ $39.63)
- $39.63 P/E (TTM): 5.55X Cap: $1.02B
- View CDZ Profile
- View Questions on CDZ
-
Vanguard U.S. Dividend Appreciation Index ETF (VGG $101.75)
- $101.75 Cap: $2.18B
- View VGG Profile
- View Questions on VGG
-
Financial Select Sector SPDR (XLF $53.80)
- $53.80 P/E (TTM): 16.85X Cap: $55.19B
- View XLF Profile
- View Questions on XLF
-
Consumer Staples Select Sector SPDR (XLP $80.32)
- $80.32 P/E (TTM): 24.24X Cap: $15.98B
- View XLP Profile
- View Questions on XLP
-
Health Care Select Sector SPDR (XLV $138.11)
- $138.11 P/E (TTM): 23.54X Cap: $34.77B
- View XLV Profile
- View Questions on XLV
-
Technology Select Sector SPDR ETF (XLK $270.88)
- $270.88 P/E (TTM): 33.5X Cap: $86.65B
- View XLK Profile
- View Questions on XLK
-
Industrial Select Sector SPDR (XLI $151.58)
- $151.58 P/E (TTM): 87.98X Cap: $23.42B
- View XLI Profile
- View Questions on XLI
-
Communication Services Select Sector SPDR Fund (XLC $117.35)
- $117.35 P/E (TTM): 70.08X Cap: $26.52B
- View XLC Profile
- View Questions on XLC
-
BMO Nasdaq 100 Equity Index ETF (ZNQ $107.98)
- $107.98 P/E (TTM): 31.84X Cap: $1.17B
- View ZNQ Profile
- View Questions on ZNQ
Q: I am coming into a $50,000 gift from aging parents, and would like to invest for my 10 month old son’s education. I want long term growth until he needs the money (probably 18 years or so). Would you recommend 100% ZSP or some other ETF? Also, should I buy in one shot as soon as I have the money ?
-
Health Care Select Sector SPDR (XLV $138.11)
- $138.11 P/E (TTM): 23.54X Cap: $34.77B
- View XLV Profile
- View Questions on XLV
-
iShares U.S. Medical Devices ETF (IHI $61.27)
- $61.27 P/E (TTM): 28.37X Cap: $4.29B
- View IHI Profile
- View Questions on IHI
Q: Health care as a sector has me puzzled. I was adding to my positions in XLV and IHI during 2023-2024. I was prompted to keep investing thinking demographics would favor growth; that elective medical procedures postponed would come roaring back in the years following Covid. Mostly good companies were held in the above ETFs, and I was comfortable investing also because of familiarity with products and services. Markets have proven me wrong. My cost base is markedly higher than valuations today. XLV is down ~5.25% over the past 12 months (year-to-date return is flat —down -0.05%).IHI, although slightly up ~4.28% YTD, has still not recovered from a 20% drop in 2022. (Losses I show are much greater and are not useable for tax).
Current officials in the US admin have no clue on how to go about drug price reforms. Worse: they don’t know that they have no clue. Reforms are necessary; and PBMs are rightly under scrutiny for opaque pricing practices. I say this notwithstanding that UNH has produced the largest dollar loss I have had in several years.
The science and med professionals who DO know how to implement sensible and substantial changes are fired and replaced by sycophantic, subservient ignorant types. Is it therefore prudent now to sell one or both of XLV and IHI and redeploy cash in other areas? OR, would one be giving up at possibly the exact wrong time? Is now finally the time that patience with XLV and IHI has a greater chance of paying off?
Current officials in the US admin have no clue on how to go about drug price reforms. Worse: they don’t know that they have no clue. Reforms are necessary; and PBMs are rightly under scrutiny for opaque pricing practices. I say this notwithstanding that UNH has produced the largest dollar loss I have had in several years.
The science and med professionals who DO know how to implement sensible and substantial changes are fired and replaced by sycophantic, subservient ignorant types. Is it therefore prudent now to sell one or both of XLV and IHI and redeploy cash in other areas? OR, would one be giving up at possibly the exact wrong time? Is now finally the time that patience with XLV and IHI has a greater chance of paying off?
Insiders
Share Information
SEC Filings
News and Media